Garweg, Justus G.; Keiper, Judith; Pfister, Isabel B; Schild, Christin (2023). Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment-A Meta-Analysis and Systematic Review. Journal of clinical medicine, 12(14) MDPI 10.3390/jcm12144671
|
Text
jcm-12-04671.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (635kB) | Preview |
Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine. We wished to identify factors related to the treatment details of IOI involving the posterior segment resulting from IVB for neovascular AMD (nAMD), if these were reported in detail. Articles were retrieved from PubMed, Scopus, ClinicalTrials, and CENTRAL using the following search terms: <Brolucizumab> AND <AMD> AND <intraocular inflammation>. The risk of bias was rated using the JBI Critical Appraisal Tool. We included 31 reports (41 patients and 46 eyes). Patients were 75.9 ± 8.5 years, and 58.5% were female. IOI occurred 41.7 ± 37.5 (median 37.0) days after treatment initiation with 2.0 ± 1.3 (1-6) IVB injections. A mean change in visual acuity of -14.6 ± 21.0 (median -6.5) letters was reported. The mean time from first IOI signs to the initiation of any anti-inflammatory treatment was 3.3 ± 6.2 days, with 63% of the patients receiving systemic corticosteroids as standard treatment. Finally, a period effect was observed, with a change in visual acuity of -25.3 ± 27.1 and -2.6 ± 7.3 letters in the chronologically first and last third, respectively, of treated eyes (effect size: r = 0.71; p = 0.006). Functional outcomes markedly improved with increasing experience in managing IOI.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology |
UniBE Contributor: |
Garweg, Justus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2077-0383 |
Publisher: |
MDPI |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
02 Aug 2023 09:13 |
Last Modified: |
25 Mar 2024 09:32 |
Publisher DOI: |
10.3390/jcm12144671 |
PubMed ID: |
37510788 |
Uncontrolled Keywords: |
brolucizumab intraocular inflammation neovascular age-related macular degeneration retinal vascular occlusion retinal vasculitis treatment outcome uveitis |
BORIS DOI: |
10.48350/185130 |
URI: |
https://boris.unibe.ch/id/eprint/185130 |
Actions (login required)
 |
Edit item |